DGFT Introduces new norm for Clobetasol Propionate: A Boon for Pharma Exporters

Last Updated on November 29, 2024 by The Health Master

Clobetasol Propionate

The Directorate General of Foreign Trade (DGFT) has taken a significant step to streamline the export process for pharmaceutical manufacturers in India with respect to clobetasol propionate.

Through a recent public notice, the DGFT has introduced a new Standard Input Output Norm (SION) specifically for clobetasol propionate, a crucial pharmaceutical compound.

What is Clobetasol Propionate?

Clobetasol propionate is a potent topical corticosteroid medication primarily used to treat severe skin conditions like psoriasis, eczema, and dermatitis.

It works by reducing inflammation and itching in the affected areas.

The New SION: A Detailed Look

The newly introduced SION, numbered A-3682, falls under the Chemical and Allied Product group (Product Code ‘A’).

It outlines the specific input requirements for exporting clobetasol propionate.

Key Points of the New SION:

• Export Product: Clobetasol Propionate
• SION Number: A-3682
• Import Item Requirement: Betamethasone – 0.95 kg per 1 kg of clobetasol propionate exported

Benefits of the New SION

The implementation of this new SION is expected to bring several benefits to the pharmaceutical export industry:

• Streamlined Export Process: The clear specification of input requirements, particularly the quantity of betamethasone needed, will simplify the export procedures.
• Efficient Trade Regulation: The SION will help in effective monitoring and regulation of exports, ensuring compliance with international trade norms.
• Enhanced Ease of Doing Business: This move aligns with the government’s ongoing efforts to improve the business environment for exporters.

In conclusion, the DGFT’s introduction of the new SION for clobetasol propionate is a positive development for the Indian pharmaceutical industry.

By providing clarity on input requirements and streamlining the export process, this move will contribute to the growth of India’s pharmaceutical exports.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.

For informative videos by The Health Master, click on the below YouTube icon:

• Key Notes on Revised Schedule M: Point No. 11 – Personnel
  December 20, 2024
• USFDA issued Form 483 with two observations to Aurobindo for API plant
  December 20, 2024
• NPPA fixed retail price of 65 formulations: December 2024
  December 20, 2024
• Key Notes on Revised Schedule M: Point No. 10 – Self Inspection
  December 19, 2024
• Medical Device recall: USFDA classifies recall of these catheters as ‘most serious’
  December 19, 2024
• NPPA: New Strategy to Curb Drug Price Hikes
  December 19, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: